448 related articles for article (PubMed ID: 31067680)
1. Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
Banik D; Moufarrij S; Villagra A
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067680
[TBL] [Abstract][Full Text] [Related]
2. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
3. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
5. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.
Zhou M; Yuan M; Zhang M; Lei C; Aras O; Zhang X; An F
Eur J Med Chem; 2021 Dec; 226():113825. PubMed ID: 34562854
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.
Shen L; Orillion A; Pili R
Epigenomics; 2016 Mar; 8(3):415-28. PubMed ID: 26950532
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: a patent review (2009 - 2011).
Carafa V; Miceli M; Altucci L; Nebbioso A
Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
Conte M; De Palma R; Altucci L
Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
12. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of HDACs--effective drugs against cancer?
Müller S; Krämer OH
Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
[TBL] [Abstract][Full Text] [Related]
15. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
Li X; Xu W
Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
[TBL] [Abstract][Full Text] [Related]
16. Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.
Singh P; Tomar RS; Rath SK
Mol Biol Rep; 2015 Nov; 42(11):1515-31. PubMed ID: 26033434
[TBL] [Abstract][Full Text] [Related]
17. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeting histone deacetylase for treatment of solid tumors.
Shi MQ; Xu Y; Fu X; Pan DS; Lu XP; Xiao Y; Jiang YZ
J Hematol Oncol; 2024 May; 17(1):37. PubMed ID: 38822399
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic agents in combined anticancer therapy.
Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
[TBL] [Abstract][Full Text] [Related]
20. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
